Vascular Endothelial Growth Factor A
Research News and Information

Monday, November 23, 2009

Prognostic value of proangiogenic cytokines in children with lymphomas.

13 Dec 2009 BACKGROUND: Angiogenesis and proangiogenic cytokines are involved in neoplastic development. The role of these processes in lymphoma formation has not been established. The aim of the study was to assess angiogenesis on the basis of serum levels of ... Read more...

VEGF expression as a prognostic marker in osteosarcoma.

29 Nov 2009 BACKGROUND: The vascular endothelial growth factor (VEGF) pathway is the key regulator of angiogenesis. In osteosarcoma baseline VEGF is of proven prognostic value but prognostic potential of post-NACT VEGF expression is largely unexplored. ... Read more...

Bevacizumab as therapy for radiation necrosis in four children with pontine gliomas.

13 Nov 2009 PURPOSE: Diffuse pontine gliomas are a pediatric brain tumor that is fatal in nearly all patients. Given the poor prognosis for patients with this tumor, their quality of life is very important. Radiation therapy provides some palliation, but can ... Read more...

Latest indexed articles for 'Vascular Endothelial Growth Factor A'

These are the very latest articles for this heading:

• Prognostic value of proangiogenic cytokines in children with lymphomas. 13 Dec 2009
• VEGF expression as a prognostic marker in osteosarcoma. 29 Nov 2009
• Rapid and persistent regression of severe new vessels on the disc in proliferative diabetic retinopathy after a single intravitreal injection of pegaptanib. 16 Nov 2009
• Bevacizumab as therapy for radiation necrosis in four children with pontine gliomas. 13 Nov 2009
• Expression and role of adrenomedullin in renal tumors and value of its mRNA levels as prognostic factor in clear-cell renal carcinoma. 13 Nov 2009
• Effect of polymorphisms in the 3' untranslated region (3'-UTR) of vascular endothelial growth factor gene on gastric cancer and peptic ulcer diseases in Japan. 30 Oct 2009
• Bevacizumab local complications. 30 Oct 2009
• Angiographic changes after bevacizumab. 30 Oct 2009
• Endothelial cells incubated with platelet-rich plasma express PDGF-B and ICAM-1 and induce bone marrow stromal cell migration. 30 Oct 2009
• Curcumin sensitizes human colorectal cancer to capecitabine by modulation of cyclin D1, COX-2, MMP-9, VEGF and CXCR4 expression in an orthotopic mouse model. 30 Oct 2009
• Hearing improvement after bevacizumab for neurofibromatosis type 2. 27 Oct 2009
• Comparison of gene delivery techniques for therapeutic angiogenesis ultrasound-mediated destruction of carrier microbubbles versus direct intramuscular injection. 25 Oct 2009
• Endothelial progenitor cells do not contribute to tumor endothelium in primary and metastatic tumors. 13 Oct 2009
• Arterial-venous segregation by selective cell sprouting: an alternative mode of blood vessel formation. 7 Oct 2009
• The glial cell response is an essential component of hypoxia-induced erythropoiesis in mice. 3 Oct 2009
• Current concerns and challenges regarding tailored anti-angiogenic therapy in cancer. 29 Sep 2009
• The expression of vascular endothelial growth factor in skeletal muscle of patients with sleep disorders. 29 Sep 2009
• The molecular basis of vascular lumen formation in the developing mouse aorta. 29 Sep 2009
• Norepinephrine-induced invasion by pancreatic cancer cells is inhibited by propranolol. 29 Sep 2009
• Elevated CD133, but not VEGF or EGFR, as a predictive marker of distant recurrence after preoperative chemoradiotherapy in rectal cancer. 29 Sep 2009

See a longer list of these articles.

Technical information about 'Vascular Endothelial Growth Factor A'

Definition: The original member of the family of endothelial cell growth factors referred to as VASCULAR ENDOTHELIAL GROWTH FACTORS. Vascular endothelial growth factor-A was originally isolated from tumor cells and referred to as "tumor angiogenesis factor" and "vascular permeability factor". Although expressed at high levels in certain tumor-derived cells it is produced by a wide variety of cell types. In addition to stimulating vascular growth and vascular permeability it may play a role in stimulating VASODILATION via NITRIC OXIDE-dependent pathways. Alternative splicing of the mRNA for vascular endothelial growth factor A results in several isoforms of the protein being produced.

Registry Number: 0

Descriptor UI: D042461

Alternative terms: Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor-A; Vascular Permeability Factor; Permeability Factor, Vascular; VEGF; VEGF-A; Vascular Endothelial Growth Factor; Vasculotropin; Glioma-Derived Vascular Endothelial Cell Growth Factor; Glioma Derived Vascular Endothelial Cell Growth Factor; GD-VEGF;

Allowable Qualifiers: administration & dosage; adverse effects; analysis; antagonists & inhibitors; biosynthesis; blood; cerebrospinal fluid; chemical synthesis; classification; deficiency; diagnostic use; drug effects; economics; genetics; history; immunology; isolation & purification; metabolism; pharmacokinetics; pharmacology; physiology; poisoning; radiation effects; secretion; standards; supply & distribution; therapeutic use; toxicity; ultrastructure; urine; chemistry; contraindications; agonists;

Tree Number: D12.644.276.100.800.200; D12.776.467.100.800.200; D23.529.100.800.200;

History Note: 2004; use VASCULAR ENDOTHELIAL GROWTH FACTOR A (NM) 2000-2002